IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 1983 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (167 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   References

 Article Access Statistics
    Viewed4725    
    Printed68    
    Emailed0    
    PDF Downloaded349    
    Comments [Add]    
    Cited by others 2    

Recommend this journal

 


 
LETTER TO EDITOR
Year : 2008  |  Volume : 74  |  Issue : 2  |  Page : 169

Vitiligo, psoriasis and imiquimod: Fitting all into the same pathway


Consultant dermatologist, Kaya Skin Clinic, Dubai, United Arab Emirates

Correspondence Address:
Bell Raj Eapen
Kaya Skin Clinic, Dubai
United Arab Emirates
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0378-6323.39717

Rights and Permissions



How to cite this article:
Eapen BR. Vitiligo, psoriasis and imiquimod: Fitting all into the same pathway. Indian J Dermatol Venereol Leprol 2008;74:169

How to cite this URL:
Eapen BR. Vitiligo, psoriasis and imiquimod: Fitting all into the same pathway. Indian J Dermatol Venereol Leprol [serial online] 2008 [cited 2017 Mar 26];74:169. Available from: http://www.ijdvl.com/text.asp?2008/74/2/169/39717


Sir,

I read with interest the letter describing imiquimod-induced vitiligo-like depigmentation. [1] There are other similar case reports [2],[3] and 68 reports of pigmentary changes related to imiquimod use listed by FDA. [4] The most widely accepted theory is that imiquimod activates the cell-mediated arm of the immune system via the stimulation of multiple pro-inflammatory cytokines which up-regulates a Type-1 cell response (Th1) that unmasks an innate predilection for the development of vitiligo. [5]

The mode of action of imiquimod involves activation of Toll-like receptors (TLR) 7 and 8, which initiates a signaling cascade leading to the production of pro-inflammatory cytokines like IFN-α and TNF-α. However, TLR 7 and 8 also initiates ubiquitin-mediated proteolysis and apoptosis through the myeloid differentiation factor 88-dependent pathway as evident from the pathway map [6] hsa04620 available from KEGG. [7] In a previous letter to IJDVL , I presented the genomic evidence for ubiquitin-mediated melanocyte-specific apoptotic process in vitiligo. [8] Hence, the ubiquitin-mediated proteolysis may be important in the pathogenesis of vitiligo-like lesions following treatment with imiquimod.

A Th1 type response with increased TNF-α is vital in the pathogenesis of psoriasis. [9] Hence, it is hardly surprising that there are several reports of imiquimod-induced psoriasis. [10],[11],[12],[13] Psoriasis is a proliferative disorder while vitiligo is an apoptotic disorder. It is interesting to note that these disparate conditions converge at a fundamental pathway level.

 
  References Top

1.Senel E, Seckin D. Imiquimod-induced vitiligo-like depigmentation. Indian J Dermatol Venereol Leprol 2007;73: 423.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]
2.Stefanaki C, Nicolaidou E, Hadjivassiliou M, Antoniou C, Katsambas A. Imiquimod-induced vitiligo in a patient with genital warts. J Eur Acad Dermatol Venereol 2006;20:755-756.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]
3.Al-Dujaili Z, Hsu S. Imiquimod-induced vitiligo. Dermatol Online J 2007;13:10.  Back to cited text no. 3    
4.Mashiah J, Brenner S. Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod. Clin Exp Dermatol 2008;33:74-76.  Back to cited text no. 4  [PUBMED]  [FULLTEXT]
5.Nouri K, Busso M, Machler BC. Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C. Cutis 1997;60:289-290.  Back to cited text no. 5  [PUBMED]  
6.Kawai T, Akira S. TLR signaling. Semin Immunol 2007;19:24-32.  Back to cited text no. 6  [PUBMED]  [FULLTEXT]
7.Aoki-Kinoshita KF, Kanehisa M. Gene Annotation and Pathway Mapping in KEGG. Methods Mol Biol 2007;396:71-92.  Back to cited text no. 7  [PUBMED]  
8.Eapen BR. VIT1 gene and vitiligo. Indian J Dermatol Venereol Leprol 2004;70:184-185.  Back to cited text no. 8  [PUBMED]  [FULLTEXT]
9.Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004;113:1664-1675.  Back to cited text no. 9  [PUBMED]  [FULLTEXT]
10.Fanti PA, Dika E, Vaccari S, Miscial C, Varotti C. Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int J Dermatol 2006;45:1464-1465.  Back to cited text no. 10  [PUBMED]  [FULLTEXT]
11.Gilliet M, Conrad C, Geiges M, Cozzio A, Thurlimann W, Burg G, et al . Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004;140:1490-1495.  Back to cited text no. 11    
12.Rajan N, Langtry JA. Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas. Clin Exp Dermatol 2006;31:140-141.  Back to cited text no. 12  [PUBMED]  [FULLTEXT]
13.Wu JK, Siller G, Strutton G. Psoriasis induced by topical imiquimod. Australas J Dermatol 2004;45:47-50.  Back to cited text no. 13  [PUBMED]  [FULLTEXT]



This article has been cited by
1 Vitiligo-like hypopigmentation associated with imiquimod treatment | [Hipopigmentación tipo vitíligo relacionada con tratamiento con imiquimod]
Monteagudo, B., Cabanillas, M., López-Mouriño, V.M., Suárez-Amor, O.
Piel. 2009; 24(9): 513
[Pubmed]
2 Hipopigmentación tipo vitíligo relacionada con tratamiento con imiquimod
Benigno Monteagudo,Miguel Cabanillas,Victor Manuel López-Mouriño,Óscar Suárez-Amor
Piel. 2009; 24(9): 513
[Pubmed] | [DOI]



 

Top
Print this article  Email this article
Previous article Next article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow